Phase II evaluation of desipramine for the treatment of hot flashes

Debra L. Barton, Charles Lawrence Loprinzi, Pamela Atherton, Jane Raymond, Tait Shanafelt, Stephanie Hines, Fran Palmieri, Teresa Rummans, Alex Adjei, Jeff A Sloan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Newer antidepressants with serotonergic effects reduce hot flashes significantly better than placebo. This pilot study was designed to test the efficacy of desipramine, an older antidepressant targeting norepinephrine, in women desiring therapy for hot flashes and to evaluate the toxicity of desipramine. Patients and Methods: In this nonrandomized trial, eligible women were required to have reported ≥ 14 bothersome hot flashes per week for ≥ 1 month. After an initial baseline week in which no study medication was taken, participants started with desipramine 25 mg daily, which was titrated to 100 mg daily by week 5. The primary endpoint was change from baseline in hot flash frequency and hot flash score. Statistical methods involved paired t tests for continuous variables and Fisher exact tests for categoric variables. Results: Twenty-six patients were enrolled on this study between March 2004 and November 2005. The decrease in mean hot flash frequency over 4 weeks of treatment was 23%, with a 31% reduction in hot flash scores. Seven patients (30%) withdrew early because of toxicities consisting of insomnia, nausea, headaches, and/or feeling frightened. Conclusion: Desipramine did not reduce hot flashes beyond the 25%-30% reduction that would be expected with placebo, based on previous work. Therefore, data from this trial do not support further study of this agent for treatment of hot flashes. It is of physiologic interest that this older antidepressant, classified as a tricyclic, did not achieve a clinically significant reduction in hot flash scores in this pilot trial.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalSupportive Cancer Therapy
Volume4
Issue number4
DOIs
StatePublished - Sep 2007

Fingerprint

Hot Flashes
Desipramine
Antidepressive Agents
Therapeutics
Placebos
Sleep Initiation and Maintenance Disorders
Nausea
Headache
Norepinephrine
Emotions

Keywords

  • Antidepressants
  • Menopause
  • Survivors
  • Symptom management

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology

Cite this

Phase II evaluation of desipramine for the treatment of hot flashes. / Barton, Debra L.; Loprinzi, Charles Lawrence; Atherton, Pamela; Raymond, Jane; Shanafelt, Tait; Hines, Stephanie; Palmieri, Fran; Rummans, Teresa; Adjei, Alex; Sloan, Jeff A.

In: Supportive Cancer Therapy, Vol. 4, No. 4, 09.2007, p. 219-224.

Research output: Contribution to journalArticle

Barton, DL, Loprinzi, CL, Atherton, P, Raymond, J, Shanafelt, T, Hines, S, Palmieri, F, Rummans, T, Adjei, A & Sloan, JA 2007, 'Phase II evaluation of desipramine for the treatment of hot flashes', Supportive Cancer Therapy, vol. 4, no. 4, pp. 219-224. https://doi.org/10.3816/SCT.2007.n.018
Barton, Debra L. ; Loprinzi, Charles Lawrence ; Atherton, Pamela ; Raymond, Jane ; Shanafelt, Tait ; Hines, Stephanie ; Palmieri, Fran ; Rummans, Teresa ; Adjei, Alex ; Sloan, Jeff A. / Phase II evaluation of desipramine for the treatment of hot flashes. In: Supportive Cancer Therapy. 2007 ; Vol. 4, No. 4. pp. 219-224.
@article{538597313f8049b18980809a76be4416,
title = "Phase II evaluation of desipramine for the treatment of hot flashes",
abstract = "Purpose: Newer antidepressants with serotonergic effects reduce hot flashes significantly better than placebo. This pilot study was designed to test the efficacy of desipramine, an older antidepressant targeting norepinephrine, in women desiring therapy for hot flashes and to evaluate the toxicity of desipramine. Patients and Methods: In this nonrandomized trial, eligible women were required to have reported ≥ 14 bothersome hot flashes per week for ≥ 1 month. After an initial baseline week in which no study medication was taken, participants started with desipramine 25 mg daily, which was titrated to 100 mg daily by week 5. The primary endpoint was change from baseline in hot flash frequency and hot flash score. Statistical methods involved paired t tests for continuous variables and Fisher exact tests for categoric variables. Results: Twenty-six patients were enrolled on this study between March 2004 and November 2005. The decrease in mean hot flash frequency over 4 weeks of treatment was 23{\%}, with a 31{\%} reduction in hot flash scores. Seven patients (30{\%}) withdrew early because of toxicities consisting of insomnia, nausea, headaches, and/or feeling frightened. Conclusion: Desipramine did not reduce hot flashes beyond the 25{\%}-30{\%} reduction that would be expected with placebo, based on previous work. Therefore, data from this trial do not support further study of this agent for treatment of hot flashes. It is of physiologic interest that this older antidepressant, classified as a tricyclic, did not achieve a clinically significant reduction in hot flash scores in this pilot trial.",
keywords = "Antidepressants, Menopause, Survivors, Symptom management",
author = "Barton, {Debra L.} and Loprinzi, {Charles Lawrence} and Pamela Atherton and Jane Raymond and Tait Shanafelt and Stephanie Hines and Fran Palmieri and Teresa Rummans and Alex Adjei and Sloan, {Jeff A}",
year = "2007",
month = "9",
doi = "10.3816/SCT.2007.n.018",
language = "English (US)",
volume = "4",
pages = "219--224",
journal = "Supportive Cancer Therapy",
issn = "1543-2912",
publisher = "Cancer Information Group, LP",
number = "4",

}

TY - JOUR

T1 - Phase II evaluation of desipramine for the treatment of hot flashes

AU - Barton, Debra L.

AU - Loprinzi, Charles Lawrence

AU - Atherton, Pamela

AU - Raymond, Jane

AU - Shanafelt, Tait

AU - Hines, Stephanie

AU - Palmieri, Fran

AU - Rummans, Teresa

AU - Adjei, Alex

AU - Sloan, Jeff A

PY - 2007/9

Y1 - 2007/9

N2 - Purpose: Newer antidepressants with serotonergic effects reduce hot flashes significantly better than placebo. This pilot study was designed to test the efficacy of desipramine, an older antidepressant targeting norepinephrine, in women desiring therapy for hot flashes and to evaluate the toxicity of desipramine. Patients and Methods: In this nonrandomized trial, eligible women were required to have reported ≥ 14 bothersome hot flashes per week for ≥ 1 month. After an initial baseline week in which no study medication was taken, participants started with desipramine 25 mg daily, which was titrated to 100 mg daily by week 5. The primary endpoint was change from baseline in hot flash frequency and hot flash score. Statistical methods involved paired t tests for continuous variables and Fisher exact tests for categoric variables. Results: Twenty-six patients were enrolled on this study between March 2004 and November 2005. The decrease in mean hot flash frequency over 4 weeks of treatment was 23%, with a 31% reduction in hot flash scores. Seven patients (30%) withdrew early because of toxicities consisting of insomnia, nausea, headaches, and/or feeling frightened. Conclusion: Desipramine did not reduce hot flashes beyond the 25%-30% reduction that would be expected with placebo, based on previous work. Therefore, data from this trial do not support further study of this agent for treatment of hot flashes. It is of physiologic interest that this older antidepressant, classified as a tricyclic, did not achieve a clinically significant reduction in hot flash scores in this pilot trial.

AB - Purpose: Newer antidepressants with serotonergic effects reduce hot flashes significantly better than placebo. This pilot study was designed to test the efficacy of desipramine, an older antidepressant targeting norepinephrine, in women desiring therapy for hot flashes and to evaluate the toxicity of desipramine. Patients and Methods: In this nonrandomized trial, eligible women were required to have reported ≥ 14 bothersome hot flashes per week for ≥ 1 month. After an initial baseline week in which no study medication was taken, participants started with desipramine 25 mg daily, which was titrated to 100 mg daily by week 5. The primary endpoint was change from baseline in hot flash frequency and hot flash score. Statistical methods involved paired t tests for continuous variables and Fisher exact tests for categoric variables. Results: Twenty-six patients were enrolled on this study between March 2004 and November 2005. The decrease in mean hot flash frequency over 4 weeks of treatment was 23%, with a 31% reduction in hot flash scores. Seven patients (30%) withdrew early because of toxicities consisting of insomnia, nausea, headaches, and/or feeling frightened. Conclusion: Desipramine did not reduce hot flashes beyond the 25%-30% reduction that would be expected with placebo, based on previous work. Therefore, data from this trial do not support further study of this agent for treatment of hot flashes. It is of physiologic interest that this older antidepressant, classified as a tricyclic, did not achieve a clinically significant reduction in hot flash scores in this pilot trial.

KW - Antidepressants

KW - Menopause

KW - Survivors

KW - Symptom management

UR - http://www.scopus.com/inward/record.url?scp=35348962753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348962753&partnerID=8YFLogxK

U2 - 10.3816/SCT.2007.n.018

DO - 10.3816/SCT.2007.n.018

M3 - Article

C2 - 18632520

AN - SCOPUS:35348962753

VL - 4

SP - 219

EP - 224

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

SN - 1543-2912

IS - 4

ER -